Events

Events

Washington DC – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”. 

Virtual – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”. 

8th ESWI 2021

Virtual – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Lyon – Oral Presentation
Delphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

ISIRV-WHO

Virtual – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

A Day @Bioaster

LyonOral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled “the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine.”

Vaccine Summit 2021

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Virtual – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”. 

Lille – Oral Presentation
Florence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial”.

Boston – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”.

Barcelona – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”.

OPTIONS X

Singapore – Oral Presentations and Posters
Alexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled “A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans”. Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present “Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model”. Two more posters entitled “OVX836 protect ferrets in flu challenge study” and “OVX836 protection is mediated by CD8 T-cells as demonstrated in mice passive transfer studies” are also presented.

Edinburgh – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses”.

Beijing – Poster
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present preclinical results of OVX836 as part of a poster entitled “OVX836 a multimerized nucleoprotein based vaccine candidate protects mice against lethal challenges of multiple strains of influenza A viruses”.

Lausanne – Oral Presentation
Dr. Fergal Hill, Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled “OVX836, a multimerized nucleoprotein (NP) induces cellular responses against NP in various animal models challenges of multiple strains of influenza A viruses”.